Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to -$10.2 million.

  • Integra Lifesciences Holdings' Cash from Financing Activities rose 4855.64% to -$10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year decrease of 10132.58%. This contributed to the annual value of $237.9 million for FY2024, which is 20345.24% up from last year.
  • Latest data reveals that Integra Lifesciences Holdings reported Cash from Financing Activities of -$10.2 million as of Q3 2025, which was up 4855.64% from -$21.1 million recorded in Q2 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Cash from Financing Activities peaked at $358.7 million during Q1 2024, and registered a low of -$162.7 million during Q1 2023.
  • Moreover, its 5-year median value for Cash from Financing Activities was -$10.7 million (2023), whereas its average is -$17.8 million.
  • In the last 5 years, Integra Lifesciences Holdings' Cash from Financing Activities tumbled by 1885220.73% in 2022 and then skyrocketed by 32047.54% in 2024.
  • Over the past 5 years, Integra Lifesciences Holdings' Cash from Financing Activities (Quarter) stood at $521000.0 in 2021, then plummeted by 18852.21% to -$97.7 million in 2022, then skyrocketed by 92.95% to -$6.9 million in 2023, then dropped by 3.77% to -$7.2 million in 2024, then plummeted by 43.29% to -$10.2 million in 2025.
  • Its Cash from Financing Activities stands at -$10.2 million for Q3 2025, versus -$21.1 million for Q2 2025 and $35.4 million for Q1 2025.